Anaeropharma Science Co. starts clinical tests in the US on cancer treatment using recombinant Bifidus bacteria

The test strain, Bifidobacterium longum (APS001F) which expresses adenosine deaminase (AD), will be administered intravenously followed by 5-fluorocytosine, leading to selective formation of highly toxic 5-fluorouracil in anaerobic environments where tumor tissue is located. The patient is also given maltose, a growth factor for Bifidobacteria. Experiments on mice and rats in Japan led to a strong enrichment of 5-FU in tumor tissue. Eisai Co. has taken an option on this system.

Anaeropharma Science press release, https://www.anaeropharma.co.jp/j/research/

Anaeropharma Science Co. starts clinical tests in the US on cancer treatment using recombinant Bifidus bacteria
Scroll to top